SS Innovations Posts Record Q2 Revenue of $13.9M, Up 39.4%
SSII sits 25% above its 52-week low of $3.11 on light trading volume (0.1× avg).
Summary
SS Innovations reported record Q2 revenue of $13.9M, up 39.4% year-over-year, driven by a 30.4% increase in SSi Mantra installations to 30 units. Gross profit rose 20% to $7.1M with a 50.9% margin, while net loss widened to $2.7M from $0.3M a year earlier on higher R&D and stock comp. First-half revenue jumped 65.6% to $25M, and the cumulative installed base reached 224 systems across 12 countries. The company also disclosed 12,272 cumulative procedures, including 175 telesurgeries, and expects FDA 510(k) review completion by end of Q1 2027 and EU CE marking by end of 2026. This follows the 10-Q filed yesterday that flagged going concern doubt and material weaknesses, making the strong revenue growth a key offsetting factor for investors.
At the time of this announcement, SSII was trading at $3.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $778.5M. The 52-week trading range was $3.11 to $10.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: FinanceWire.